NasdaqGM:ADMA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States.


Snowflake Analysis

High growth potential with adequate balance sheet.

Share Price & News

How has ADMA Biologics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ADMA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.1%

ADMA

0.4%

US Biotechs

2.3%

US Market


1 Year Return

-30.5%

ADMA

28.5%

US Biotechs

6.7%

US Market

Return vs Industry: ADMA underperformed the US Biotechs industry which returned 29% over the past year.

Return vs Market: ADMA underperformed the US Market which returned 6.1% over the past year.


Shareholder returns

ADMAIndustryMarket
7 Day-2.1%0.4%2.3%
30 Day1.1%7.2%1.5%
90 Day3.7%23.9%17.8%
1 Year-30.5%-30.5%29.7%28.5%9.0%6.7%
3 Year-19.1%-19.1%31.7%27.4%36.6%27.7%
5 Year-70.7%-70.7%-5.3%-10.6%64.2%46.2%

Price Volatility Vs. Market

How volatile is ADMA Biologics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ADMA Biologics undervalued compared to its fair value and its price relative to the market?

2.54x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ADMA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ADMA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ADMA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ADMA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ADMA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ADMA is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.5x).


Next Steps

Future Growth

How is ADMA Biologics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

71.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADMA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: ADMA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ADMA's is expected to become profitable in the next 3 years.

Revenue vs Market: ADMA's revenue (36.6% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: ADMA's revenue (36.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ADMA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ADMA Biologics performed over the past 5 years?

-29.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ADMA is currently unprofitable.

Growing Profit Margin: ADMA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ADMA is unprofitable, and losses have increased over the past 5 years at a rate of -29.7% per year.

Accelerating Growth: Unable to compare ADMA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ADMA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: ADMA has a negative Return on Equity (-56.53%), as it is currently unprofitable.


Next Steps

Financial Health

How is ADMA Biologics's financial position?


Financial Position Analysis

Short Term Liabilities: ADMA's short term assets ($165.5M) exceed its short term liabilities ($13.9M).

Long Term Liabilities: ADMA's short term assets ($165.5M) exceed its long term liabilities ($100.3M).


Debt to Equity History and Analysis

Debt Level: ADMA's debt to equity ratio (99.8%) is considered high.

Reducing Debt: ADMA's debt to equity ratio has reduced from 111.9% to 99.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ADMA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ADMA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 34.8% each year


Next Steps

Dividend

What is ADMA Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ADMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ADMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ADMA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ADMA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ADMA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.0yrs

Average management tenure


CEO

Adam Grossman (43yo)

8.75yrs

Tenure

US$1,702,022

Compensation

Mr. Adam S. Grossman is the Co-Founder of ADMA Biologics, Inc. and has been its Chief Executive Officer and President since October 2011 and 2007 respectively. Mr. Grossman serves as the President, Chief E ...


CEO Compensation Analysis

Compensation vs Market: Adam's total compensation ($USD1.70M) is about average for companies of similar size in the US market ($USD1.37M).

Compensation vs Earnings: Adam's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Adam Grossman
Co-Founder8.75yrsUS$1.70m1.09% $2.7m
Jerrold Grossman
Co-Founder & Vice Chairman of the Board8.75yrsUS$137.21k0.22% $530.0k
Brian Lenz
Executive VP & CFO8.17yrsUS$1.12m0.037% $90.9k
James Mond
Executive VP8yrsUS$1.24m0.026% $62.8k
Kim Tripodo
Executive Director & Head of Human Resource and Administrative Operations0.083yrno datano data
Kaitlin Kestenberg
Vice President of Complianceno datano datano data
Mathew Peters
Vice President & General Counsel0.50yrno datano data
Michael Least
Vice President of Sales & Commercial Operationsno datano datano data
Drew Pantello
Vice President of Marketing & Corporate Developmentno datano datano data
Gene Wetzstein
Executive Director & Head of Scientific Engagementno datano datano data

8.0yrs

Average Tenure

60yo

Average Age

Experienced Management: ADMA's management team is seasoned and experienced (8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Adam Grossman
Co-Founder8.75yrsUS$1.70m1.09% $2.7m
Jerrold Grossman
Co-Founder & Vice Chairman of the Board8.75yrsUS$137.21k0.22% $530.0k
Bryant Fong
Independent Director8.17yrsUS$125.81kno data
Steven Elms
Independent Chairmanno dataUS$137.21kno data
Lawrence Guiheen
Independent Director8yrsUS$125.61k0.082% $200.9k
John DeVincenzo
Member of Scientific Advisory Board6.08yrsno datano data
Roy Chemaly
Member of Scientific Advisory Board6.08yrsno datano data
Jordan Orange
Member of Scientific Advisory Board6.08yrsno datano data
E. Stiehm
Member of Scientific Advisory Board6.08yrsno datano data
Jean-Laurent Casanova
Member of Scientific Advisory Boardno datano datano data

7.0yrs

Average Tenure

57yo

Average Age

Experienced Board: ADMA's board of directors are considered experienced (7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.6%.


Top Shareholders

Company Information

ADMA Biologics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ADMA Biologics, Inc.
  • Ticker: ADMA
  • Exchange: NasdaqGM
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$244.357m
  • Shares outstanding: 86.35m
  • Website: https://www.admabiologics.com

Number of Employees


Location

  • ADMA Biologics, Inc.
  • 465 State Route 17
  • Ramsey
  • New Jersey
  • 7446
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ADMANasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDOct 2013

Biography

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/11 00:11
End of Day Share Price2020/07/10 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.